• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Harvard Bioscience Schedules Second Quarter 2024 Earnings Conference Call for August 8, 2024 at 10:00 AM ET

    8/2/24 8:00:00 AM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HBIO alert in real time by email

    HOLLISTON, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended June 30, 2024 before the market opens on August 8, 2024, and will hold a conference call to discuss the results at 10:00 a.m. Eastern Time. 

    Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. 

    Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

    Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience's website. 

    About Harvard Bioscience 

    Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world's leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

    For more information, please visit our website at www.harvardbioscience.com.

    Company Contact:

    Jennifer Cote

    Chief Financial Officer

    (508) 893-3120

    Investors Contact:

    Three Part Advisors

    Sandy Martin / Erol Girgin / William Shelmire

    [email protected]

    (214) 616-2207



    Primary Logo

    Get the next $HBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBIO

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/10/2023$3.00 → $4.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings

    $HBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Harvard Bioscience Appoints John Duke to Board of Directors

      HOLLISTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced the appointment of John Duke to its board of directors, effective June 2, 2025. Mr. Duke will also serve on the audit and nominating and governance committees. The Company also announced that Katherine Eade has been named Lead Independent Director of the Company's board of directors. "We are pleased to welcome John to Harvard Bioscience's board," said Katherine Eade, Lead Independent Director. "John brings deep experience in life science tools and business execution and has a track record of driving growth and operational excellence." Jim Green, President and CEO, sa

      6/2/25 4:57:22 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Announces First Quarter 2025 Financial Results

      HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) (the "Company") today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, "First quarter revenues were in line with our expectations, reflecting typical Q4 to Q1 seasonality as well as uncertainty surrounding NIH funding and the evolving tariff situation, especially in relation to sales to China." We are excited by the emerging adoption of our breakthrough MeshMEA™ organoid systems by academic and biopharma customers and encouraged by the market reception of our new SoHo™ telemetry systems. In addition, we remain focused on managing costs and ex

      5/12/25 7:00:00 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Schedules First Quarter 2025 Earnings Conference Call for May 12, 2025 at 8:00 AM ET

      HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (NASDAQ:HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, wi

      5/5/25 4:45:00 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Duke John D

      3 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/9/25 9:08:53 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Interim CFO Frost Mark T was granted 100,000 shares, increasing direct ownership by 400% to 125,000 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      5/14/25 3:52:18 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • New insider Frost Mark T claimed ownership of 25,000 shares (SEC Form 3)

      3 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      5/14/25 3:49:59 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Harvard Biosci downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Harvard Biosci from Overweight to Sector Weight

      4/9/25 8:35:36 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Biosci upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Harvard Biosci from Speculative Buy to Buy and set a new price target of $4.00 from $3.00 previously

      3/10/23 8:11:48 AM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • KeyCorp reiterated coverage on Harvard Bioscience with a new price target

      KeyCorp reiterated coverage of Harvard Bioscience with a rating of and set a new price target of $9.00 from $6.00 previously

      3/10/21 5:04:31 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    SEC Filings

    See more
    • Harvard Bioscience Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      6/23/25 4:46:04 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      6/13/25 4:45:46 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Harvard Bioscience Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - HARVARD BIOSCIENCE INC (0001123494) (Filer)

      6/2/25 5:00:21 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $HBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/14/24 4:02:29 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

      4 - HARVARD BIOSCIENCE INC (0001123494) (Issuer)

      6/7/24 4:02:24 PM ET
      $HBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials